Skip to main content
Journal cover image

Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.

Publication ,  Journal Article
McCormack, M; Urban, TJ; Shianna, KV; Walley, N; Pandolfo, M; Depondt, C; Chaila, E; O'Conner, GD; Kasperavičiūtė, D; Radtke, RA; Heinzen, EL ...
Published in: Pharmacogenomics
March 2012

AIMS: An association between carbamazepine-induced hypersensitivity and HLA-A*3101 has been reported in populations of both European and Asian descent. We aimed to investigate HLA-A*3101 and other common variants across the genome as markers for cutaneous adverse drug reactions (cADRs) attributed to lamotrigine and phenytoin. MATERIALS & METHODS: We recruited patients with lamotrigine-induced cADRs (n = 46) and patients with phenytoin-cADRs (n = 44) and the 1958 British birth cohort was used as a control (n = 1296). HLA-A*3101 was imputed from genome-wide association study data. We applied genome-wide association to study lamotrigine- and phenytoin-induced cADR, and total cADR cases combined. RESULTS: Neither HLA-A*3101 nor any other genetic marker significantly predicted lamotrigine- or phenytoin-induced cADRs. CONCLUSION: HLA-A*3101 does not appear to be a predictor for lamotrigine- and phenytoin-induced cADRs in Europeans. Our genome-wide association study results do not support the existence of a clinically relevant common variant for the development of lamotrigine- or phenytoin-induced cADRs. As a predictive marker, HLA-A*3101 appears to be specific for carbamazepine-induced cADRs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

March 2012

Volume

13

Issue

4

Start / End Page

399 / 405

Location

England

Related Subject Headings

  • Triazines
  • Polymorphism, Single Nucleotide
  • Phenytoin
  • Pharmacology & Pharmacy
  • Lamotrigine
  • Humans
  • HLA-A Antigens
  • Genome-Wide Association Study
  • Drug Hypersensitivity
  • Carbamazepine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McCormack, M., Urban, T. J., Shianna, K. V., Walley, N., Pandolfo, M., Depondt, C., … Cavalleri, G. L. (2012). Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics, 13(4), 399–405. https://doi.org/10.2217/pgs.11.165
McCormack, Mark, Thomas J. Urban, Kevin V. Shianna, Nicole Walley, Massimo Pandolfo, Chantal Depondt, Elijah Chaila, et al. “Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.Pharmacogenomics 13, no. 4 (March 2012): 399–405. https://doi.org/10.2217/pgs.11.165.
McCormack M, Urban TJ, Shianna KV, Walley N, Pandolfo M, Depondt C, et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012 Mar;13(4):399–405.
McCormack, Mark, et al. “Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.Pharmacogenomics, vol. 13, no. 4, Mar. 2012, pp. 399–405. Pubmed, doi:10.2217/pgs.11.165.
McCormack M, Urban TJ, Shianna KV, Walley N, Pandolfo M, Depondt C, Chaila E, O’Conner GD, Kasperavičiūtė D, Radtke RA, Heinzen EL, Sisodiya SM, Delanty N, Cavalleri GL. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012 Mar;13(4):399–405.
Journal cover image

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

March 2012

Volume

13

Issue

4

Start / End Page

399 / 405

Location

England

Related Subject Headings

  • Triazines
  • Polymorphism, Single Nucleotide
  • Phenytoin
  • Pharmacology & Pharmacy
  • Lamotrigine
  • Humans
  • HLA-A Antigens
  • Genome-Wide Association Study
  • Drug Hypersensitivity
  • Carbamazepine